NoticiasCon ayuda de IA
China Accepts Telix NDA For Illuccix PSMA-PET Prostate Cancer Imaging
Telix secures NDA acceptance in China for Illuccix, marking a major step toward expanding PSMA-PET imaging in prostate cancer care.
Por Vaibhavi M.
Experto en la materia (B.Pharm) · Pharma Now
20 ene 20262 min de lectura
Reportaje con ayuda de IA
Reviewed by Vaibhavi M., Experto en la materia (B.Pharm) · Pharma Now
Telix Pharmaceuticals has announced that China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for TLX591-Px (Illuccix®), a kit used to prepare ^68Ga-PSMA-11 for prostate cancer imaging. Illuccix is Telix’s lead diagnostic imaging agent for prostate cancer and represents a key step in expanding access to PSMA-PET imaging in China.
TemasNoticias
Written by
Vaibhavi M.
Experto en la materia (B.Pharm) · Pharma Now
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Más de Pharma News
Todos los artículos →
Noticias
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Vaibhavi M. · 29 sept 2026
Noticias
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Vaibhavi M. · 29 sept 2026
Noticias
Celmade recibe una carta de advertencia de la FDA por la venta de toxina botulínica inyectable no autorizada en EE. UU.
Vaibhavi M. · 29 sept 2026
Discussion